{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:09:15Z","timestamp":1778735355644,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jns.2026.125947","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:08:17Z","timestamp":1777410497000},"page":"125947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy"],"prefix":"10.1016","volume":"486","author":[{"given":"Liza M.Y.","family":"Gelissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn T.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125947_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1474-4422(05)70117-4","article-title":"Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis","volume":"4","author":"Hemmer","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.125947_bb0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.125947_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00023210-200923050-00003","article-title":"Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes","volume":"23","author":"Deisenhammer","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2026.125947_bb0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archneurol.2010.21","article-title":"Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis","volume":"67","author":"van der Voort","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2026.125947_bb0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archneurol.2010.218","article-title":"Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta","volume":"67","author":"Sominanda","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2026.125947_bb0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1352458513503597","article-title":"Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development","volume":"20","author":"Hegen","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2026.125947_bb0035","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/1352458516684023","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations","volume":"23","author":"van Kempen","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2026.125947_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000904","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","volume":"8","author":"Toorop","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2026.125947_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2007.01989.x","article-title":"Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta","volume":"15","author":"Gibbs","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.125947_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.125947_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type i interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:19:53Z","timestamp":1778732393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26002297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":11,"alternative-id":["S0022510X26002297"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125947","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125947"}}